WHO antibacterial preclinical pipeline review

WHO's first global review of antibacterial products in preclinical development that are being developed in 145 institutions around the ...

2023 Antibacterial agents in clinical and preclinical development

This report presents an analysis of antibacterial agents in preclinical (fourth annual review) and clinical (sixth annual review) development.

WHO Antibacterial Pipeline Review: Update thru 31 Dec 2023

Based on these summaries, you will not be surprised by the report's sobering main conclusion: “Overall, antibacterial agents in the clinical ...

Multi-year analysis of the global preclinical antibacterial pipeline

This review examines the trends in preclinical development and attempts to identify gaps and potential opportunities to overcome the numerous hurdles.

The global preclinical antibacterial pipeline - Nature

Overall, the current preclinical antibacterial pipeline consists of 407 highly diverse projects from 314 institutions, most of which are small ...

Antibacterial agents in preclinical and clinical development

However, the report emphasises that the antibiotic pipeline and the number of antibacterial agents approved in recent years is insufficient to ...

WHO: AMR Policy Brief and Preclinical pipeline data call • AMR ...

Scope: Traditional and non-traditional antibacterial candidates covering the WHO bacterial priority pathogens as well as other resistant ...

Antibiotics in the clinical pipeline as of December 2022 - Nature

To assess whether these activities are improving the status quo, we have monitored antibacterial drug development since 2011 with reviews ...

The Global Preclinical Antibacterial Pipeline | ASM.org

The process for review of the antibacterial pipeline, the progress and gaps in antibiotic discovery and the opportunities to overcome the ...

Exploring the Global Clinical and Preclinical Antibacterial Pipelines

The preclinical antibacterial pipeline refers to all antibacterial drug candidates currently in preclinical developmental stages globally.

Antibiotics in the clinical pipeline as of December 2022 - PMC

Since the 2019 review [24] in this series, two new small molecule antibacterials (Table 1, Figs. 1 and 2), levonadifloxacin (1) (as its prodrug ...

The Global Preclinical Antibacterial Pipeline - Editors in Conversation

The pipeline of antibiotic discovery is a major necessity due to the continuous evolution of resistance to currently used antimicrobials.

"The global preclinical antibacterial pipeline" by Kevin Outterson

A review of the clinical antibacterial drug pipeline was recently published, but comprehensive information about the global preclinical pipeline is unavailable.

2021 Antibacterial agents in clinical and preclinical development

This report presents an analysis of antibacterial agents in preclinical (third annual review) and clinical (fifth annual review) development ...

Overview of Antibacterial Agents in Preclinical and Clinical ...

WHO annual antibacterial R&D pipeline review. 2. Data collection: literature & desk review, survey, targeted outreach, online data call ( ...

WHO 2020 report on the antibacterial production and development ...

The review highlighted that in the clinical antibacterial pipeline there are currently 43 traditional antibiotics and combinations with a new therapeutic ...

A novel pre-clinical antibacterial pipeline database | PLOS ONE

To shed light further upstream on the preclinical pipeline the WHO has undertaken a review of the antibacterial preclinical pipeline and ...

[PDF] The global preclinical antibacterial pipeline - Semantic Scholar

The innovative potential of the preclinical pipeline compared with the clinical pipeline is encouraging but fragile and much more work, focus and funding ...

The Antibacterial Research and Development Pipeline Needs ...

From the review, the preclinical antibacterial pipeline seems to be dynamic and scientifically diverse, including research projects from ...

Evaluating the innovative potential of the global antibacterial pipeline

This narrative review centres on systemic direct-acting small molecules that are currently undergoing or have recently completed clinical ...